<DOC>
	<DOC>NCT01140425</DOC>
	<brief_summary>The purpose of this study is to assess the affect that PF-00232798 has on QT interval. A prolonged QT interval is a risk factor for arrhythmias.</brief_summary>
	<brief_title>Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male and/or female subjects of nonchildbearing potential between the ages of 21 and 55 years, inclusive. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Use of tobacco or nicotinecontaining products in excess of the equivalent of 5 cigarettes per day. 12lead ECG demonstrating QTc &gt;450 msec at screening. Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 halflives preceding the first dose of study medication. History of orthostatic symptoms or orthostatic hypotension at screening. Pregnant or nursing females; females of childbearing potential.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>PF-00232798</keyword>
	<keyword>CCR5</keyword>
	<keyword>QT</keyword>
	<keyword>QTc</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>